摘要
目的评价亚胺培南/西司他丁钠(IMP)与美罗培南(MEP)治疗重症感染的经济学效果。方法运用最小成本分析法,分别对上述2种治疗方案治疗重症感染的临床效果及成本进行评价。结果亚胺培南/西司他丁钠组和美罗培南组治疗重症感染的总有效率分别为93.33%(28/30)和85.71%(24/28),差异无统计学意义(χ^2=4.89,P=0.08);成本-效果比(C/E)分别为40.35和71.69,与亚胺培南/西司他丁钠组相比,美罗培南组每增加一个单位效果需多花费(△C/AE)312.16元。结论亚胺培南/西司他丁钠组的成本-效果比优于美罗培南组,亚胺培南/西司他丁钠治疗重症感染有明显的药物经济学优势。
Objective To evaluate the economic effects of Imipenem-Cilastatin Sodium and Meropenem for severe infection. Methods The therapeutic effects and costs of the two therapeutic schemes for severe infection were evaluated by using cost-minimization analysis. Results The total effective rates of Imipenem- cilastatin group and Meropenem group in the treatment severe infection were 93.33% (28/30) and 85.71% (24/28), the difference were not statistically significant ( χ^2 = 4. 89, P = 0. 082 ). The cost-effectiveness ratio (C/E) were 40. 35 and 71.69 respectively. The cost of every unit increment of effectiveness for Meropenem group were 312. 16 Yuan,more than that of the Imipenem-cilastatin group. Conclusion Cost-effectiveness ratio of Imipenem-cilastatin is superior to that of Meropenem, and Imipenem-cilastatin has obvious pharmacoeconomics advantage over Meropenem for severe infections.
出处
《中国综合临床》
2013年第4期387-389,共3页
Clinical Medicine of China